Korro Bio to Showcase Innovations at Upcoming Conferences
Korro Bio, Inc. (Nasdaq: KRRO) is a leading biopharmaceutical company focused on advancing genetic medicines through RNA editing technology. The company has announced its participation in several important investor and scientific conferences, providing a valuable opportunity for Korro's leadership team to share their innovative approaches to tackling both rare and common diseases.
Participation in Upcoming Conferences
Korro Bio's management will take part in various conferences to highlight their groundbreaking work. The first event is the 2024 Wells Fargo Healthcare Conference, where Chief Executive Officer and President, Ram Aiyar, Ph.D., along with Chief Financial Officer, Vineet Agarwal, will engage in one-on-one investor meetings on September 4, 2024.
Presentations and Discussions
Next, Korro will be featured at the RNA Leaders USA Congress. On September 5, 2024, Chief Operating Officer, Todd Chappell, will present on their proprietary OPERA™ platform. His talk, titled “Using a Novel ADAR Editing Platform to Address Unmet Needs in Liver and CNS Therapeutics,” promises to offer insightful discussions about the applications of RNA editing in the field of medical science.
Annual Global Investment Conference
Dr. Aiyar will speak again at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024. He will provide updates on Korro’s initiatives and vision, while Mr. Agarwal will discuss the company’s financial strategies and upcoming projects.
Focus on Clinical Trials Through Advanced Research
In the following week, Korro's Chief Medical Officer, Kemi Olugemo, M.D., FANN, will represent the company at the International Society for CNS Clinical Trials and Methodology (ISCTM) 2024 Autumn Conference. On September 12, 2024, she will lead a session focused on the “Use of neurophysiological markers to design and enrich clinical trials in rare neurological disorders.” This session is vital for developing new therapies aimed at neurological conditions, underscoring Korro’s dedication to advancing clinical research.
Webcast and Information Access
For those interested in following these discussions live, the H.C. Wainwright presentation will be webcast and can be accessed through the “Events & Presentations” section on Korro’s investor page. A replay will be available for 30 days, ensuring stakeholders can stay updated on Korro's ongoing developments and innovations.
About Korro Bio
Korro Bio is at the forefront of biopharmaceutical innovation, specializing in a new class of genetic medicines designed to treat a variety of diseases using its proprietary RNA editing platform. By leveraging the body’s natural RNA editing processes, Korro Bio aims to make precise modifications, offering the potential for greater precision and long-term tolerability compared to traditional DNA editing methods.
Through an oligonucleotide-based approach, Korro is making significant progress in developing medicines that can be delivered using established methods and regulatory pathways, which are essential for ensuring safe and effective therapeutic options for patients.
Investor and Media Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
Frequently Asked Questions
What is Korro Bio known for?
Korro Bio is known for its innovative approach to genetic medicines, particularly its focus on RNA editing technologies to treat a variety of diseases.
What conferences will Korro be attending?
Korro will participate in the Wells Fargo Healthcare Conference, RNA Leaders USA Congress, H.C. Wainwright Annual Global Investment Conference, and the ISCTM Autumn Conference.
What presentations will Korro be delivering?
Key presentations will feature discussions on their OPERA™ platform for RNA editing, as well as insights into clinical trials for neurological disorders.
Where can I find more information about Korro Bio's presentations?
Details about Korro’s presentations can be found on the “Events & Presentations” page of their investor website, which includes live streams and replays.
How does Korro's RNA editing technology differ from traditional methods?
Korro's RNA editing technology enables precise and temporary edits, which may offer improvements in specificity and long-term tolerability for patients compared to traditional DNA editing techniques.
